Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

Cited In for PubMed (Select 17163383)

1.

Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity.

Ross KA, Loyd H, Wu W, Huntimer L, Ahmed S, Sambol A, Broderick S, Flickinger Z, Rajan K, Bronich T, Mallapragada S, Wannemuehler MJ, Carpenter S, Narasimhan B.

Int J Nanomedicine. 2014 Dec 30;10:229-43. doi: 10.2147/IJN.S72264. eCollection 2015.

2.

Seasonal influenza vaccination among Mexican migrants traveling through the Mexico-US border region.

Ejebe IH, Zhang X, Rangel MG, Martinez-Donate AP.

Prev Med. 2015 Feb;71:57-60. doi: 10.1016/j.ypmed.2014.12.004. Epub 2014 Dec 13.

PMID:
25514546
3.

The Split Virus Influenza Vaccine rapidly activates immune cells through Fcγ receptors.

O'Gorman WE, Huang H, Wei YL, Davis KL, Leipold MD, Bendall SC, Kidd BA, Dekker CL, Maecker HT, Chien YH, Davis MM.

Vaccine. 2014 Oct 14;32(45):5989-97. doi: 10.1016/j.vaccine.2014.07.115. Epub 2014 Sep 6.

PMID:
25203448
4.

Zoonotic infections with avian influenza A viruses and vaccine preparedness: a game of "mix and match".

Pascua PN, Choi YK.

Clin Exp Vaccine Res. 2014 Jul;3(2):140-8. doi: 10.7774/cevr.2014.3.2.140. Epub 2014 Jun 20. Review.

5.

Rapid strategy for screening by pyrosequencing of influenza virus reassortants--candidates for live attenuated vaccines.

Shcherbik SV, Pearce NC, Levine ML, Klimov AI, Villanueva JM, Bousse TL.

PLoS One. 2014 Mar 19;9(3):e92580. doi: 10.1371/journal.pone.0092580. eCollection 2014.

6.

CD4 T cell help is limiting and selective during the primary B cell response to influenza virus infection.

Alam S, Knowlden ZA, Sangster MY, Sant AJ.

J Virol. 2014 Jan;88(1):314-24. doi: 10.1128/JVI.02077-13. Epub 2013 Oct 23.

7.

An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans.

Sansyzbay AR, Erofeeva MK, Khairullin BM, Sandybayev NT, Kydyrbayev ZK, Mamadaliyev SM, Kassenov MM, Sergeeva MV, Romanova JR, Krivitskaya VZ, Kiselev OI, Stukova MA.

Clin Vaccine Immunol. 2013 Aug;20(8):1314-9. doi: 10.1128/CVI.00096-13. Epub 2013 Jun 26.

8.

Molecular signature of high yield (growth) influenza a virus reassortants prepared as candidate vaccine seeds.

Ramanunninair M, Le J, Onodera S, Fulvini AA, Pokorny BA, Silverman J, Devis R, Arroyo JM, He Y, Boyne A, Bera J, Halpin R, Hine E, Spiro DJ, Bucher D.

PLoS One. 2013 Jun 11;8(6):e65955. doi: 10.1371/journal.pone.0065955. Print 2013.

9.

H5N1 vaccines in humans.

Baz M, Luke CJ, Cheng X, Jin H, Subbarao K.

Virus Res. 2013 Dec 5;178(1):78-98. doi: 10.1016/j.virusres.2013.05.006. Epub 2013 May 28. Review.

10.

Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza A virus in mice.

Kim EH, Lee JH, Pascua PN, Song MS, Baek YH, Kwon HI, Park SJ, Lim GJ, Decano A, Chowdhury MY, Seo SK, Song MK, Kim CJ, Choi YK.

Virol J. 2013 Apr 3;10:104. doi: 10.1186/1743-422X-10-104.

11.

M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A.

Ibañez LI, Roose K, De Filette M, Schotsaert M, De Sloovere J, Roels S, Pollard C, Schepens B, Grooten J, Fiers W, Saelens X.

PLoS One. 2013;8(3):e59081. doi: 10.1371/journal.pone.0059081. Epub 2013 Mar 18.

12.

Immunobiology of influenza vaccines.

Gomez Lorenzo MM, Fenton MJ.

Chest. 2013 Feb 1;143(2):502-10. doi: 10.1378/chest.12-1711. Review.

13.

Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli.

Wang W, Huang B, Jiang T, Wang X, Qi X, Gao Y, Tan W, Ruan L.

PLoS One. 2012;7(12):e52488. doi: 10.1371/journal.pone.0052488. Epub 2012 Dec 21.

14.

Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice.

Huang B, Wang W, Li R, Wang X, Jiang T, Qi X, Gao Y, Tan W, Ruan L.

Virol J. 2012 Dec 29;9:322. doi: 10.1186/1743-422X-9-322.

15.

Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection.

Koutsonanos DG, Vassilieva EV, Stavropoulou A, Zarnitsyn VG, Esser ES, Taherbhai MT, Prausnitz MR, Compans RW, Skountzou I.

Sci Rep. 2012;2:357. doi: 10.1038/srep00357. Epub 2012 Apr 12.

16.

Local spatial and temporal processes of influenza in Pennsylvania, USA: 2003-2009.

Stark JH, Sharma R, Ostroff S, Cummings DA, Ermentrout B, Stebbins S, Burke DS, Wisniewski SR.

PLoS One. 2012;7(3):e34245. doi: 10.1371/journal.pone.0034245. Epub 2012 Mar 28.

17.

Influenza update: a review of currently available vaccines.

Clayville LR.

P T. 2011 Oct;36(10):659-84. No abstract available.

18.

Influenza virus vaccines: lessons from the 2009 H1N1 pandemic.

Broadbent AJ, Subbarao K.

Curr Opin Virol. 2011 Oct;1(4):254-62. doi: 10.1016/j.coviro.2011.08.002. Review.

19.

Design, synthesis, and evaluation of novel small molecule inhibitors of the influenza virus protein NS1.

Jablonski JJ, Basu D, Engel DA, Geysen HM.

Bioorg Med Chem. 2012 Jan 1;20(1):487-97. doi: 10.1016/j.bmc.2011.10.026. Epub 2011 Oct 19.

20.

Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus.

Santiago FW, Fitzgerald T, Treanor JJ, Topham DJ.

Vaccine. 2011 Nov 8;29(48):8888-97. doi: 10.1016/j.vaccine.2011.09.069. Epub 2011 Sep 28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk